Optimistic Outlook on uniQure’s AMT-130 Program Amidst Regulatory Progress and Market Volatility

TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating today.

Joseph Thome has given his Buy rating due to a combination of factors including the promising progress of uniQure’s AMT-130 program. The company has shown positive developments in its interactions with the FDA, particularly regarding the Accelerated Approval pathway for AMT-130, which targets Huntington’s disease, a condition with significant unmet medical needs. The receipt of Breakthrough Therapy Designation and positive feedback from FDA consultants bolster confidence in the program’s potential success.
Despite recent volatility in the stock price, Thome remains optimistic about uniQure’s prospects, noting that the fundamental value proposition and likelihood of AMT-130’s success remain intact. The appointment of Dr. Prasad as the head of CBER initially caused concern due to his views on gene therapy, but his recent statements suggest a more flexible approach for rare disease treatments. Thome anticipates further positive data updates from the ongoing Phase I/II program, which could reinforce the efficacy of AMT-130 and support its regulatory approval process.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.